vs
Side-by-side financial comparison of Immunovant, Inc. (IMVT) and JOINT Corp (JYNT). Click either name above to swap in a different company.
JOINT Corp is the larger business by last-quarter revenue ($15.2M vs $8.4M, roughly 1.8× Immunovant, Inc.). JOINT Corp runs the higher net margin — 6.5% vs -899.0%, a 905.5% gap on every dollar of revenue. On growth, Immunovant, Inc. posted the faster year-over-year revenue change (140.7% vs 3.1%). JOINT Corp produced more free cash flow last quarter ($334.7K vs $-59.8M).
Immunovant, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative monoclonal antibody therapies for patients with serious, rare autoimmune and inflammatory diseases. Its lead product candidate covers multiple autoimmune indications, with core U.S. operations and a global market expansion strategy.
The Joint Corp is a leading operator and franchisor of chiropractic care clinics primarily serving the U.S. market. It offers accessible, affordable routine chiropractic services, membership-based care plans, and caters to consumers seeking non-invasive musculoskeletal pain management and wellness support.
IMVT vs JYNT — Head-to-Head
Income Statement — Q4 FY2024 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $8.4M | $15.2M |
| Net Profit | $-75.3M | $991.1K |
| Gross Margin | — | 81.4% |
| Operating Margin | -896.2% | 4.9% |
| Net Margin | -899.0% | 6.5% |
| Revenue YoY | 140.7% | 3.1% |
| Net Profit YoY | -26.7% | 5510.5% |
| EPS (diluted) | $-0.50 | $0.06 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $15.2M | ||
| Q3 25 | — | $13.4M | ||
| Q2 25 | — | $13.3M | ||
| Q1 25 | — | $13.1M | ||
| Q4 24 | — | $14.7M | ||
| Q3 24 | — | $30.2M | ||
| Q2 24 | — | $30.3M | ||
| Q1 24 | $8.4M | $29.7M |
| Q4 25 | — | $991.1K | ||
| Q3 25 | — | $855.0K | ||
| Q2 25 | — | $93.4K | ||
| Q1 25 | — | $967.8K | ||
| Q4 24 | — | $17.7K | ||
| Q3 24 | — | $-3.2M | ||
| Q2 24 | — | $-3.6M | ||
| Q1 24 | $-75.3M | $947.0K |
| Q4 25 | — | 81.4% | ||
| Q3 25 | — | 80.1% | ||
| Q2 25 | — | 79.1% | ||
| Q1 25 | — | 77.3% | ||
| Q4 24 | — | 78.4% | ||
| Q3 24 | — | 90.7% | ||
| Q2 24 | — | 90.7% | ||
| Q1 24 | — | 90.9% |
| Q4 25 | — | 4.9% | ||
| Q3 25 | — | 1.2% | ||
| Q2 25 | — | -8.6% | ||
| Q1 25 | — | -5.2% | ||
| Q4 24 | — | 5.5% | ||
| Q3 24 | — | -1.6% | ||
| Q2 24 | — | -5.9% | ||
| Q1 24 | -896.2% | -1.4% |
| Q4 25 | — | 6.5% | ||
| Q3 25 | — | 6.4% | ||
| Q2 25 | — | 0.7% | ||
| Q1 25 | — | 7.4% | ||
| Q4 24 | — | 0.1% | ||
| Q3 24 | — | -10.5% | ||
| Q2 24 | — | -11.9% | ||
| Q1 24 | -899.0% | 3.2% |
| Q4 25 | — | $0.06 | ||
| Q3 25 | — | $0.06 | ||
| Q2 25 | — | $0.01 | ||
| Q1 25 | — | $0.06 | ||
| Q4 24 | — | $0.01 | ||
| Q3 24 | — | $-0.21 | ||
| Q2 24 | — | $-0.24 | ||
| Q1 24 | $-0.50 | $0.06 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $635.4M | $23.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $617.8M | $15.1M |
| Total Assets | $666.4M | $61.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $23.6M | ||
| Q3 25 | — | $29.7M | ||
| Q2 25 | — | $29.8M | ||
| Q1 25 | — | $21.9M | ||
| Q4 24 | — | $25.1M | ||
| Q3 24 | — | $20.7M | ||
| Q2 24 | — | $17.5M | ||
| Q1 24 | $635.4M | $18.7M |
| Q4 25 | — | $15.1M | ||
| Q3 25 | — | $22.7M | ||
| Q2 25 | — | $23.2M | ||
| Q1 25 | — | $22.8M | ||
| Q4 24 | — | $20.7M | ||
| Q3 24 | — | $20.5M | ||
| Q2 24 | — | $23.2M | ||
| Q1 24 | $617.8M | $26.2M |
| Q4 25 | — | $61.0M | ||
| Q3 25 | — | $69.4M | ||
| Q2 25 | — | $73.2M | ||
| Q1 25 | — | $80.1M | ||
| Q4 24 | — | $83.2M | ||
| Q3 24 | — | $79.6M | ||
| Q2 24 | — | $82.4M | ||
| Q1 24 | $666.4M | $85.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-59.7M | $1.8M |
| Free Cash FlowOCF − Capex | $-59.8M | $334.7K |
| FCF MarginFCF / Revenue | -714.4% | 2.2% |
| Capex IntensityCapex / Revenue | 1.8% | 9.9% |
| Cash ConversionOCF / Net Profit | — | 1.86× |
| TTM Free Cash FlowTrailing 4 quarters | $-214.6M | $-1.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $1.8M | ||
| Q3 25 | — | $1.8M | ||
| Q2 25 | — | $868.6K | ||
| Q1 25 | — | $-3.7M | ||
| Q4 24 | — | $9.4M | ||
| Q3 24 | — | $3.4M | ||
| Q2 24 | — | $-973.5K | ||
| Q1 24 | $-59.7M | $2.8M |
| Q4 25 | — | $334.7K | ||
| Q3 25 | — | $1.5M | ||
| Q2 25 | — | $363.6K | ||
| Q1 25 | — | $-4.0M | ||
| Q4 24 | — | $8.2M | ||
| Q3 24 | — | $3.2M | ||
| Q2 24 | — | $-1.2M | ||
| Q1 24 | $-59.8M | $2.4M |
| Q4 25 | — | 2.2% | ||
| Q3 25 | — | 10.9% | ||
| Q2 25 | — | 2.7% | ||
| Q1 25 | — | -30.8% | ||
| Q4 24 | — | 55.9% | ||
| Q3 24 | — | 10.6% | ||
| Q2 24 | — | -4.1% | ||
| Q1 24 | -714.4% | 8.1% |
| Q4 25 | — | 9.9% | ||
| Q3 25 | — | 2.4% | ||
| Q2 25 | — | 3.8% | ||
| Q1 25 | — | 2.5% | ||
| Q4 24 | — | 8.1% | ||
| Q3 24 | — | 0.8% | ||
| Q2 24 | — | 0.9% | ||
| Q1 24 | 1.8% | 1.3% |
| Q4 25 | — | 1.86× | ||
| Q3 25 | — | 2.07× | ||
| Q2 25 | — | 9.30× | ||
| Q1 25 | — | -3.82× | ||
| Q4 24 | — | 532.98× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 2.97× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
IMVT
Segment breakdown not available.
JYNT
| Transferred At Point In Time | $12.8M | 84% |
| Transferred Over Time | $2.4M | 16% |
